Case: Patents/International Trade (Fed. Cir.)

The Federal Circuit noted that its previous opinion issued in this case misstates one standard of review, and alters its statement that “We review the Commission’s claim construction without deference and its underlying factual findings for clear error. See Teva Pharmaceuticals USA Inc. v. Sandoz Inc., 574 U.S. 318, 332 (2015),” to state “We review the Commission’s claim construction without deference and its underlying factual findings for substantial evidence. See Kyocera Senco Industrial Tools Inc. v. International Trade Commission, 22 F.4th 1369, 1378 (Fed. Cir. 2022).” The court stated that this alteration changes nothing about the case-specific analysis set ...